In a significant move to modernize the over-the-counter (OTC) pharmaceutical landscape, global CDMO giant Catalent has announced a strategic commercial supply agreement with Mantra, an innovator specializing in single-serve oral gel products. This partnership marks a pivotal shift in how consumers may soon access everyday relief, moving away from traditional tablets, capsules, and syrups toward a more portable and convenient format.
Under the terms of the agreement, Catalent will provide comprehensive end-to-end services for Mantra’s oral gel platform. This includes formulation development, commercial-scale manufacturing, and specialized packaging, all of which will be centralized at Catalent’s facility in St. Petersburg, Florida.
The collaboration centers on Mantra’s proprietary gel technology, which is designed to address three primary consumer needs: occasional sleeplessness, general pain relief, and menstrual relief. Unlike conventional medicinal formats, Mantra’s products are packaged in compact, single-serve pouches. This design allows for precise, pre-measured doses that can be taken anywhere, at any time, without the need for water.
Aris Gennadios, PhD, Group President of Pharma and Consumer Health at Catalent, emphasized the milestone nature of the deal. “This is the first OTC unit-dose gel technology manufactured by Catalent, and we are proud to support the commercialization of Mantra’s portfolio,” Gennadios stated. He noted that the partnership aligns with Catalent’s broader mission to leverage its infrastructure and quality systems to provide the necessary speed and scale for health innovators looking to disrupt the market.
For Mantra, the partnership is a vital step toward scaling their vision of a more user-friendly medical experience. Simon More, CEO and Founder of Mantra, suggested that while consumer habits in almost every other health category have evolved, the delivery methods for everyday medicine have remained stagnant.
“We built Mantra to rethink that experience through a modern format, clean formulations, and a more convenient approach to everyday relief,” More said. “Partnering with Catalent gives us the development expertise, manufacturing capabilities, and scale to bring that vision to market.”
Industry analysts note that this development reflects a growing trend in the pharmaceutical sector: the push for “patient-centric” delivery systems. By simplifying the act of taking medicine, these companies hope to improve consumer compliance and overall satisfaction. Single-serve gels are increasingly viewed as a superior alternative to liquids or solids, as they eliminate the measurement errors associated with syrups and the swallowing difficulties often reported by consumers using large pills.
As the industry continues to monitor the evolution of the self-care market, Catalent has signaled that this agreement is just the beginning. The company intends to continue expanding its footprint in the OTC space, positioning itself as the primary partner for innovators looking to bring modern, convenient solutions to the global consumer health stage.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
